Abstract:Although biological therapies, including the monoclonal antibody directed against the α 4 β 7 integrin, vedolizumab, have revolutionized the treatment of patients with inflammatory bowel disease (IBD), response and remission to this therapy are not universal. Up to 30% of patients with Crohn's disease (CD) and ulcerative colitis (UC) do not respond at all, and up to 70% of initial responders only partially respond, with many patients losing response over time. Many of these undesired therapeutic outcomes can b… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.